Company Overview of Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation, through its subsidiaries, discovers, develops, manufactures, and markets human and animal health care products in the United States. It offers cardiovascular, respiratory, HIV, immunology, central nervous system, and urology products; active pharmaceutical ingredients; oral liquids, tablets, and capsules; and products for the treatment of diseases in dogs, cats, horses, cattle, and swine. The company also provides over-the-counter health care products, including Dulcolax, which is used for occasional constipation and irregularity problems; Zantac that is used for the prevention and relief of heartburn; and Mirapex ER, a tablet for the signs and symptoms of i...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1986
Key Executives for Boehringer Ingelheim Corporation
Chief Executive Officer and President
Chairman of the Board of Managing Directors
Vice President of Sales and Marketing
Compensation as of Fiscal Year 2014.
Boehringer Ingelheim Corporation Key Developments
Boehringer and Eli Lilly Revise Operational Structure of Diabetes Alliance
Nov 3 14
Boehringer Ingelheim and Eli Lilly and Company have announced that they are revising the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90% of the alliance's anticipated market opportunity will continue their co-promotion work. In all other countries, the companies will exclusively commercialize the respective molecules they brought to the alliance. The changes will be implemented starting January 1, 2015. The scope of the alliance will remain unchanged in the following 17 countries: US, Germany, Italy, Spain, France, UK, Republic of Ireland, Portugal, Canada, Japan, China, Australia, New Zealand, South Korea, Taiwan, Brazil, and Mexico. Under a revised agreement, Boehringer Ingelheim and Lilly will exclusively commercialize the respective molecules they brought to the alliance in all other countries under revised financial terms that will include an upfront payment and ongoing payments paid to Lilly in lieu of commission payments in those markets.
Boehringer Ingelheim Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 02:45 PM
Sep 10 14
Boehringer Ingelheim Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 02:45 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Imran Nasrullah, Director, Innovation Sourcing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|